

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**

GenCore version 5.1.3  
Copyright (c) 1993 - 2002 Compugen Ltd.

OM protein - nucleic search, using frame\_plus\_p2n model

Run on: November 9, 2002, 04:34:22 ; Search time 298 Seconds  
(without alignments)  
1435.838 Million cell updates/sec

Title: US-09-895-298A-83

Perfect score: 1002

Sequence: 1 MANNOPSPKAMRASQMTFF.....HDSGLDRSRVQEGNPRA 190

Scoring table:

BLOSUM62	
Xgapop 10.0 , Xgapext 0.5	
Ygapop 10.0 , Ygapext 0.5	
Fgapop 6.0 , Fgapext 7.0	
Delop 6.0 , Delext 7.0	

Searched: 2185239 segs, 112599159 residues

Total number of hits satisfying chosen parameters: 4370478

Minimum DB seq length: 0  
Maximum DB seq length: 200000000

Post-processing: Minimum Match 0%  
Maximum Match 100%

Listing first 45 summaries

Command line parameters:

-MODEL=frame+\_p2n.model -DEV=xlp  
-Q=/cga2\_1/USPTO.spool/US09895298/rumat\_06112002\_160415\_2322/app\_query.fasta.1.327  
-DB=N\_Geneseq.101002 -QFMT=fastap -SUFFIX=ring -MINMATCH=0.1 -LOOPCL=0  
-LOOPEXT=0 -UNITS=bits -START=1 -END=-1 -MATRIX=blomsum2 -TRANS=human40.cdf1  
-LIST=45 -DOCALIGN=200 -THR\_SCORE=pct -THR\_MAX=100 -THR\_MIN=0 -ALIGN=15  
-MODE=LOCAL -OUTFMT=pl0 -NORM=ext -HEADSIZE=500 -MINLEN=0 -MAXLEN=200000000  
-USER=US09895298 -GCN1.1\_79 -runat\_06112002\_160415\_2322 -NCPU=6 -ICPU=3  
-NO\_XLPHY -NO\_MMAB -LARGEQUERY -NEG\_SCORES=0 -WAIT -LONGLOG -DEV.TIMEOUT=120  
-WARN\_TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -Fgapop=6 -Fgapext=7  
-YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database :

N\_Geneseq.101002:\*  
1: /SID2/gcgdata/geneseq/geneseqn\_emb1/NA1980.DAT:\*  
2: /SID2/gcgdata/geneseq/geneseqn\_emb1/NA1981.DAT:\*  
3: /SID2/gcgdata/geneseq/geneseqn\_emb1/NA1982.DAT:\*  
4: /SID2/gcgdata/geneseq/geneseqn\_emb1/NA1983.DAT:\*  
5: /SID2/gcgdata/geneseq/geneseqn\_emb1/NA1984.DAT:\*  
6: /SID2/gcgdata/geneseq/geneseqn\_emb1/NA1985.DAT:\*  
7: /SID2/gcgdata/geneseq/geneseqn\_emb1/NA1986.DAT:\*  
8: /SID2/gcgdata/geneseq/geneseqn\_emb1/NA1987.DAT:\*  
9: /SID2/gcgdata/geneseq/geneseqn\_emb1/NA1988.DAT:\*  
10: /SID2/gcgdata/geneseq/geneseqn\_emb1/NA1989.DAT:\*  
11: /SID2/gcgdata/geneseq/geneseqn\_emb1/NA1990.DAT:\*  
12: /SID2/gcgdata/geneseq/geneseqn\_emb1/NA1991.DAT:\*  
13: /SID2/gcgdata/geneseq/geneseqn\_emb1/NA1992.DAT:\*  
14: /SID2/gcgdata/geneseq/geneseqn\_emb1/NA1993.DAT:\*  
15: /SID2/gcgdata/geneseq/geneseqn\_emb1/NA1994.DAT:\*  
16: /SID2/gcgdata/geneseq/geneseqn\_emb1/NA1995.DAT:\*  
17: /SID2/gcgdata/geneseq/geneseqn\_emb1/NA1996.DAT:\*  
18: /SID2/gcgdata/geneseq/geneseqn\_emb1/NA1997.DAT:\*  
19: /SID2/gcgdata/geneseq/geneseqn\_emb1/NA1998.DAT:\*  
20: /SID2/gcgdata/geneseq/geneseqn\_emb1/NA1999.DAT:\*  
21: /SID2/gcgdata/geneseq/geneseqn\_emb1/NA2000.DAT:\*  
22: /SID2/gcgdata/geneseq/geneseqn\_emb1/NA2001A.DAT:\*  
23: /SID2/gcgdata/geneseq/geneseqn\_emb1/NA2001B.DAT:\*  
24: /SID2/gcgdata/geneseq/geneseqn\_emb1/NA2002.DAT:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1002	100.0	1097	22 ABA08605	Human LAK-4p homol
2	1002	100.0	1097	22 AAK53221	Human polynucleoti
3	1002	100.0	1219	22 AAF82463	Human CASB6411-rel
4	1002	100.0	1312	22 AAK52237	Human polynucleoti
5	1002	100.0	1461	21 AAI78402	Human secreted pro
6	1002	100.0	1813	22 AAH18131	Human cDNA sequenc
7	1002	100.0	1960	22 AAF82462	Human CASB6411-rel
8	1002	100.0	2243	21 AAF84684	cDNA encoding a hu
9	1002	100.0	2407	22 AAF82460	Human CASB6411 cDN
10	1002	100.0	2521	22 AAF82461	Alternatively spli
11	953	95.1	1194	23 ABV22463	Human prostate exp
12	953	95.1	1194	23 ABV25683	Human prostate exp
13	953	95.1	1194	23 ABV28278	Human prostate exp
14	620	61.9	470	22 AAL18591	Human breast cancer
15	614	61.3	501	22 AAL09919	Human breast cancer
16	391.5	39.1	777	22 AAH08034	Human breast cancer
17	391	39.0	617	23 ABV12915	Human cDNA clone (
18	387	38.6	286	23 ABV08852	Human prostate exp
19	315	31.4	233	22 AAL10187	Human breast cancer
20	306	30.5	197	22 AAL19767	Human breast cancer
21	293	29.2	2902	24 ABQ54905	Human ovarian anti
22	285	28.4	590	23 ABV34041	Human prostate exp
23	285	28.4	590	23 ABV42908	Human prostate exp
24	266	26.5	555	22 AAL20351	Human breast cancer
25	212	21.2	402	22 AAF65737	Novel human polynu
26	177	17.7	454	22 AAF58847	Human foetal liver
27	177	17.7	454	22 AAK07004	Human brain expres
28	177	17.7	454	22 AAK32745	Human bone marrow
29	177	17.7	454	22 AAI38558	Probe #7244 used t
30	177	17.7	454	22 AAS07543	Human genome-deriv
31	172	17.2	498	22 AAL11452	Human breast cancer
32	157	15.7	523	23 ABV03746	Human prostate exp
33	148	14.8	94	22 ABA71379	Human foetal liver
34	148	14.8	94	22 AAK19696	Human brain expres
35	148	14.8	94	22 AAK45716	Human bone marrow
36	148	14.8	94	22 AAI51641	Human genome-deriv
37	148	14.8	545	24 ABS19993	Human secreted pro
38	124.5	12.4	1633	22 AAS21352	Human cDNA sequenc
39	107.5	10.7	2703	22 AAK94324	Human full-length
40	104.5	10.4	6391	22 AAL26423	Human breast cancer
41	104.5	10.4	5929	23 ABL05865	Drosophila melanog
42	101.5	10.1	5027	23 AAS92296	DNA encoding novel
43	97	9.7	1442	20 AAX13617	Enterococcus faeca
44	93.5	9.3	486	22 AAH84071	Pongo pygmaeus Olf

## ALIGNMENTS

RESULT 1

ABA08605 ABA08605 standard; cDNA: 1097 BP.

AC ABA08605;

XX 11-JAN-2002 (first entry)

DE Human LAK-4p homologue-encoding cDNA, SEQ ID NO:381.

XX Human; cytokine; cell proliferation; cell differentiation; growth factor;

XX haematopoiesis regulation; tissue growth; immunomodulator; activin;

KW inhibin; chemotaxis; chemokinesis; thrombolysis; oncogenesis;

KW proliferation; metastasis; cancer; tumour; haematopoietic disorder;

KW myeloid cell disorder; lymphoid cell disorder; asthma; arthritis;

KW chronic inflammatory condition; proliferative retinopathy;

KW atherosclerosis; coronary heart disease; arterial ischaemia;

KW bone disorder; osteoporosis; vascular growth disorder;

KW tissue regeneration; wound healing; infection; immune disorder;  
KW cell culture; drug screening; gene therapy; antiinflammatory;  
KW antistatic; antiarthritic; haemostatic; antiarteriosclerotic;  
KW cytostatic; osteopathic; vasotropic; cardiant; virucide; antibacterial;  
KW antifungal; vulnerrary; antitumor; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200157188-A2.  
XX  
PD 09-AUG-2001.  
XX  
PF 05-FEB-2001: 2001WO-US03800.  
XX  
PR 03-FEB-2000: 2000US-0496914.  
PR 27-APR-2000: 2000US-0560875.  
XX  
PA (HYSE-) HYSEQ INC.  
XX  
PI Tang YT, Liu C, Drmanac RT;  
PI WPI: 2001-457740/49.  
DR P-PSDB; ABB11361.  
DR  
XX  
PT Human proteins and DNA encoding sequences useful for preventing,  
PT treating or ameliorating a medical condition in a mammalian subject  
PT e.g. arthritis and cancer -  
XX  
PS Claim 1: Page 473: 1963pp; English.  
XX  
CC Sequences ABB10981-ABB12330 represent 1350 novel human polypeptides, and  
CC sequences ABA08225-ABA09574 represent nucleic acids encoding them. The  
CC invention also relates to vectors and recombinant host cells comprising a  
CC nucleotide of the invention, methods of producing the novel polypeptides,  
CC antibodies against the polypeptides, methods of detecting the nucleotides  
CC or polypeptides in a sample, and methods of identifying compounds which  
CC bind to polypeptides of the invention. Although novel, many of the  
CC polypeptides of the invention have homology to known proteins, thereby  
CC giving an insight into their probable biological activities, and hence  
CC potential therapeutic applications. The polypeptides of the invention may  
CC have various activities, including cytokine, cell proliferation or cell  
CC differentiation activities; stem cell growth factor activity;  
CC haematopoiesis regulatory activity; tissue growth activity;  
CC immunomodulatory activity; activin- or inhibin-related activities;  
CC chemotactic or chemokinetic activities; haemostatic, thrombotic or  
CC thrombolytic activities; receptor or ligand activities; or may be  
CC involved in oncogenesis, cancer cell proliferation or metastasis.  
CC Depending on their biological activities, polypeptides and nucleotides of  
CC the invention are useful for preventing, treating or ameliorating medical  
CC conditions, e.g., by protein or gene therapy. Such conditions include  
CC cancers, haematopoietic disorders (e.g., myeloid or lymphoid cell  
CC disorders), chronic inflammatory conditions (e.g., asthma or arthritis),  
CC proliferative retinopathy, atherosclerosis, coronary heart disease,  
CC arterial ischaemia, bone disorders (e.g., osteoporosis), and abnormal  
CC vascular growth. Polypeptides involved with tissue regeneration and  
CC repair (or nucleic acids encoding them) may be used to promote wound  
CC healing (e.g., of burns, incisions and ulcers), while those with  
CC immunomodulatory activities may be used in the treatment of viral,  
CC bacterial and fungal infections in addition to immune disorders.  
CC Polypeptides with growth factor activity may be used in cell cultures to  
CC promote cell growth. For example, such polypeptides may be used to  
CC manipulate stem cells in culture to give rise to neuroepithelial cells  
CC that can be used to augment or replace cells damaged by illness,  
CC autoimmune disease or accidental damage. The polypeptides and nucleotides  
CC may also be used in the diagnosis of the above conditions, and in drug  
CC screening techniques. The present sequence represents a cDNA encoding a  
CC novel human polypeptide of the invention.  
XX  
SQ Sequence 1097 BP: 288 A; 246 C; 247 G; 316 T; 0 other;

Alignment Scores:  
Pred. No.: 1,69e-108 Length: 1097  
Score: 1002.00 Matches: 190

Percent Similarity: 100.00% Conservative: 0  
Best Local Similarity: 100.00% Mismatches: 0  
Query Match: 100.00% Indels: 0  
DB: 22 Gaps: 0  
US-09-895-298a-83 (1-190) x ABA08605 (1-1097)  
QY 1 MetMetAsnPhcInDroProSerLysAlaTrpAlaAlaSerGlnMetThrPhePhe 20  
DB 269 ATGATGAATTTCCAGCTCCGAGCAAAAGCTGGCGGCTCAGATGATGACTTCTTC 328  
QY 21 IlePheLeuLeuPhePheProSerPheThrGlyValLeuCysThrLeuAlaIleThrIle 40  
DB 329 ATCTTCTGCTCTTTTCCATCTTCACCGGGGCTTGTCACCTGGCCATCAGCAGTC 388  
QY 41 TrpArgLeuLysProSerAlaAspCysGlyProPheArgGlyLeuProPheIleHis 60  
DB 389 TGGAGATTGAAGCTTCAGCTGACTGCGCTTTTCGAGGTCGTGCTCTTCATTCAC 448  
QY 61 SerIleTyrSerTrpIleAspThrIleSerThrArgProGlyTyrIleTrpValValTrp 80  
DB 449 TCCATCTACAGCTGGATCGACACCTTAAGTACACGCGCTGACTGAGGTGGTTGG 508  
QY 81 IleTyrArgAsnLeuIleGlySerValHisPhePhePheIleLeuThrIleValLeu 100  
DB 509 ATCTATCGAAGACCTCATTTGAAAGTGCACCTCTTTTATCTCACCCTCATTTGTGTA 568  
QY 101 IleIleThrTyrIleTyrTrpGlnIleThrGlnGlyValArgLysIleMetIleArgLeuLeu 120  
DB 569 ATCATCACTATCTTACTGCGCAGATCACAGAGGAGGAAAGATTGTGTAAGCTGCTC 628  
QY 121 HisGlnGlnIleLeuAsnGlnGlyLysAspLysMetPheLeuIleGlnLysLeuIleLys 140  
DB 629 CATGACCAATCATCTTAATGAGGCAAAATTAATTTCTCTGATGAAATAATTGATCAAG 688  
QY 141 LeuGlnAspMetGlnLysLysAlaAsnProSerSerLeuValLeuGlnArgArgGluVal 160  
DB 689 CTCGACGATATGAGAAAGAAAGCAACCCAGCTCAGTTGTTGGAAAGAGAGGTTG 748  
QY 161 GlnGlnGlnGlnPheLeuHisLeuGlnGlyLysHisAspGlySerLeuAspLeuArgSerArg 180  
DB 749 GAGCAACAAAGCGTTTGGCATTTGGGGGGAACGATGAGCGAGTTCGATTCGATCTACA 808  
QY 181 ArgSerValGlnGlnGlyLysAsnProArgAla 190  
DB 809 AGATCAGTTCAAGAAAGTAAATCAAGGCC 838  
RESULT 2  
ID AAK53221 standard; cDNA: 1097 BP.  
XX  
AC AAK53221;  
XX  
DT 06-NOV-2001 (first entry)  
XX  
DE Human polynucleotide SEQ ID NO 2750.  
XX  
XX Human: cytokine; cell proliferation; cell differentiation; gene therapy;  
KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;  
KW tissue growth factor; immunomodulatory; cancer; leukaemia;  
KW nervous system disorder; arthritis; inflammation; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200157190-A2.  
XX  
PD 09-AUG-2001.  
XX  
PF 05-FEB-2001: 2001WO-US04098.  
XX  
PR 03-FEB-2000: 2000US-0496914.  
PR 27-APR-2000: 2000US-0560875.  
PR 20-JUN-2000: 2000US-0598075.

PR 19-JUL-2000; 2000US-0620325.  
PR 01-SEP-2000; 2000US-0654936.  
PR 15-SEP-2000; 2000US-0663561.  
PR 20-OCT-2000; 2000US-0693325.  
PR 30-NOV-2000; 2000US-0728422.  
XX  
PA (HYSE-) HYSEQ INC.  
PI Tang YT, Liu C, Drmanac RT, Asundi V, Zhou P, Xu C, Cao Y, Ma Y;  
PI Zhao QA, Wang D, Wang J, Zhang J, Ren F, Chen R, Wang ZW;  
PI Xue AJ, Yang Y, Wejhrman T, Goodrich R;  
XX  
DR WPI: 2001-476283/51.  
DR P-PSDB; AAM80088.  
XX  
PT Nucleic acids encoding polypeptides with cytokine-like activities,  
PT useful in diagnosis and gene therapy -  
XX  
PS Claim 1; Page 4962; 6221pp; English.  
XX  
CC The invention relates to polynucleotides (AAK51456-AAK53435) and the  
CC encoded polypeptides (AAM78323-AAAM80302) that exhibit activity elating to  
CC cytokine, cell proliferation or cell differentiation or which may induce  
CC production of other cytokines in other cell populations. The  
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or  
CC peptide therapy. The polypeptides have various cytokine-like activities,  
CC e.g. stem cell growth factor activity, hematopoiesis regulating  
CC activity, tissue growth factor activity, immunomodulatory activity and  
CC activin/inhibin activity and may be useful in the diagnosis and/or  
CC treatment of cancer, leukemia, nervous system disorders, arthritis and  
CC inflammation.  
CC Note: Records for SEQ ID NO 2110 (AAK52581), 2111 (AAK52582) and 3666  
CC (AAM80020) are omitted as the relevant pages from the sequence listing  
CC were missing at the time of publication.  
XX  
SQ Sequence 1097 BP; 288 A; 246 C; 247 G; 316 T; 0 other;

Alignment Scores:  
Pred. No.: 1.69e-108 Length: 1097  
Score: 1002.00 Matches: 190  
Percent Similarity: 100.00% Conservative: 0  
Best Local Similarity: 100.00% Mismatch: 0  
Query Match: 100.00% Indels: 0  
DB: 22 Gaps: 0

US-09-895-298a-83 (1-190) x AAK53221 (1-1097)

QY 1 MetMetAspGlnProProSerLysAlaTrpArgAlaSerGlnMetMetThrPhePhe 20  
DB 269 ATGATGATTTCCAGCCCTCCAGCAAGCCTGCGGCTCACAATGATGATCTTCTTC 328  
QY 21 IlePheLeuLeuPhePheProSerPheThrGlyValLeuCysThrLeuAlaIleThrIle 40  
DB 329 ATCTTCTGCTCTTTTCCATCCTTCAACCGGGGCTCTGTGACACCTGGCCATCACCATT 388  
QY 41 TrpArgLeuLysProSerAlaAspCysGlyProPheArgGlyLeuProLeuPheIleHis 60  
DB 389 TGGAGATTGAAGCCTTCAGCTGACGTGCGCTTTTCAGAGGCTCTCTTCATTTAC 448  
QY 61 SerIleYrSerTrpIleAspThrLeuSerThrArgProGlyTyrLeuTrpValAlaTrp 80  
DB 449 TCCATCTACAGCTGATGACACCTTAGTACACGCGCTGCTACTGTGGGTGTTTGG 508  
QY 81 IleYrArgAsnLeuIleGlySerValHisPhePheIleLeuThrLeuIleValLeu 100  
DB 509 ATCTATCGGAACCTCATTTGGAAGTGTGACCTCTTTTCATCTCACCCTCATTTGGCTA 568  
QY 101 IleIleThrTrpLeuTyrTrpGlnIleThrGlnGlyArgGlyIleMetIleArgLeuLeu 120  
DB 569 ATCATCACCCTACTTACTGCGAGATCACAGAGGAGGAAGATTATGATTAAGGCTGCTC 628  
QY 121 HisGlnIleIleAsnGlnGlyLysAspLysMetPheLeuIleGlnLysLeuIleLys 140

DB 629 CATGAGCAGATCATTAATGAGGCGCAAGATAAATGTTCTCTGATAGAAAATTCATCAAG 688  
QY 141 LeuGlnAspMetGlnLysLysAlaAsnProSerSerIleValLeuGlnArgGluVal 160  
DB 689 CTGCAGGATATGAGAAAGAAACCCACAGCTCCTGTTCTGAAAAGGAGAGGCTG 748  
QY 161 GlnGlnGlnGlyPheLeuHisLeuGlnLysAspGlySerLeuAspLeuArgSerArg 180  
DB 749 GAGCAACAAGGCTTTTGTGATTTGGGGGACATGATGGCAGCTTGTGATCTAG 808  
QY 181 ArgSerValGlnGlnGlyLysProArgAla 190  
DB 809 AGATCAGTTCAAGAGGTAATCAAGGGCC 838  
RESULT 3  
AAAF82463  
ID AAF82463 standard; cDNA; 1219 BP.  
AC AAF82463;  
XX  
DT 29-JUN-2001 (first entry)  
DE Human CASB6411-related cDNA #2.  
XX  
KW Human: CASB6411; vaccine; gene therapy; immunoprophylaxis;  
KW ovarian cancer; colon cancer; autoimmune disease; ss.  
OS Homo sapiens.  
XX  
FH Key location/Qualifiers  
FH CDS 1..576  
FH */\*tag= a*  
FH */partial*  
FH */note= "this sequence does not contain a start codon"*  
XX  
PN WO200123417-A2.  
XX  
PD 05-APR-2001.  
XX  
PF 27-SEP-2000; 2000WO-EP09500.  
XX  
PR 30-SEP-1999; 99GB-0023154.  
PR 07-JUL-2000; 2000GB-0016839.  
XX  
PA (SMIK ) SMITHKLINE BEECHAM BIOLOGICALS.  
XX  
PI Vinals De Bassols YC;  
PI  
DR WPI: 2001-316133/33.  
DR P-PSDB; AAB83082.  
XX  
PT Novel CASB6411 polypeptides useful in diagnostics, and as vaccines for  
PT prophylactic and therapeutic treatment of cancers, particularly ovarian  
PT and colon cancers, autoimmune diseases and related conditions -  
XX  
PS Claim 32; Page 66-67; 95pp; English.  
XX  
CC The present sequence is provided in a specification relating  
CC to CASB6411 polypeptides comprising a sequence having at least 70%  
CC identity to a sequence of 460 or 154 amino acids fully defined in  
CC the specification. CASB6411 polypeptides and polynucleotides are  
CC useful for treating a subject by immunoprophylaxis or therapy.  
CC The CASB6411 polypeptides are useful in diagnostics, and as  
CC vaccines for prophylactic and therapeutic treatment of cancers,  
CC particularly ovarian and colon cancers, autoimmune diseases and related  
CC conditions. CASB6411 polypeptides are also useful for the  
CC structure-based design of agonists, antagonists or inhibitors of the  
CC polypeptide.  
XX  
SQ Sequence 1219 BP; 346 A; 260 C; 275 G; 338 T; 0 other;

Alignment Scores: 1.97e-108 Length: 1219  
Pred. No.: 1.97e-108 Length: 1219

Score: 1002.00 Matches: 190  
 Percent Similarity: 100.00% Conservative: 0  
 Best Local Similarity: 100.00% Mismatches: 0  
 Query Match: 100.00% Indels: 0  
 DB: 22 Gaps: 0

US-09-895-298a-83 (1-190) x AAF82463 (1-1219)

QY 1 MetMetAsnPhgInProProSerLysAlaTrpArgAlaSerGlnMetMetThrPhePhe 20  
 DB 4 ATGATGAATTTCCAGCCTCGAGCAAGCCTGGCGGCTCAGACAGATGACTTTCTTC 63  
 QY 21 IlePheLeuLeuPhePheProSerPheThrGlyValLeuCysThrLeuAlaIleThrIle 40  
 DB 64 ATCTTCTGCTCTTTTCCATCTTTCACCGGGGCTTGGACCTGGCCATCCACATC 123  
 QY 41 TrpArgLeuLysProSerAlaAspCysGlyProPheArgGlyLeuProLeuPheIleHis 60  
 DB 124 TGGAGATTAAGCCTTCAGCTGACTGTGGCCCTTTTCGAGGTCTGCTCTTCATTCAC 183  
 QY 61 SerIleTySerTrpIleAspThrLeuSerThrArgProGlyTyrLeuTrpValValTrp 80  
 DB 184 TCCATGTACAGCTGATCCAGACACCTAAGTACACGGCTGGCTACCTGGGTGTGTTGG 243  
 QY 81 IleTyArgAsnLeuIleGlySerValHisPhePheIleLeuThrLeuIleValLeu 100  
 DB 244 ATCTATCGGAACCTCATTTGGAAGTGTGCACCTTTTTCATCTTCACCTCATTTGTGCTG 303  
 QY 101 IleIleThrTyrLeuTyrTrpGlnIleThrGlnGlyArgLysIleMetIleArgLeuLeu 120  
 DB 304 ATCATACCTATCTTACTGCGCAGATCACAGAGGAAGATTTTGATTAAGGCTGCTC 363  
 QY 121 HisGlnGlnIleIleAsnGlnGlyLysAspLysMetPheLeuIleGlnLysLeuIleLys 140  
 DB 364 CAGGACACATCTTTATATGAGGCAAGATAAATGTTCTGCTGATAAAAAATTGATCMAAG 423  
 QY 141 LeuGlnAspMetGlnLysLysAlaAsnProSerSerLeuValLeuGlnArgArgGlnVal 160  
 DB 424 CTGCAGATATGTGGAAGAAGCAACCCAGCTCACTTGTCTGGAAGAGAGAGGTG 483  
 QY 161 GlnGlnGlnGlnGlyPheLeuHisLeuGlnGlnHisAspGlySerLeuAspLeuArgSerArg 180  
 DB 484 GACCAACAAGGCTTTTGGATTTGGGGGAACATGATGGCAGTCTTGACCTTGCATCTAGA 543  
 QY 181 ArgSerValGlnGlnGlnLysAsnProArgAla 190  
 DB 544 AGATCACTTCAAGAGATTAATCCAGGGCC 573

RESULT 4  
 AAK52237  
 ID AAK52237 standard; cDNA; 1312 BP.  
 XX  
 AC AAK52237;  
 XX  
 DT 06-NOV-2001 (first entry)  
 XX  
 DE Human polynucleotide SEQ ID NO 782.  
 XX  
 KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;  
 KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;  
 KW tissue growth factor; immunomodulatory; cancer; leukaemia;  
 KW nervous system disorder; arthritis; inflammation; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200157190-A2.  
 XX  
 PD 09-AUG-2001.  
 XX  
 PF 05-FEB-2001; 2001WO-US04098.  
 XX  
 PR 03-FEB-2000; 2000US-0496914.  
 PR 27-APR-2000; 2000US-0560875.

PR 20-JUN-2000; 2000US-0598075.  
 PR 19-JUL-2000; 2000US-0620325.  
 PR 01-SEP-2000; 2000US-0654936.  
 PR 15-SEP-2000; 2000US-0663561.  
 PR 20-OCT-2000; 2000US-0693325.  
 PR 30-NOV-2000; 2000US-0728422.

XX (HYSE-) HYSEQ INC.

XX Tang YT, Liu C, Drmanac RT, Asundi V, Zhou P, Xu C, Gao Y, Ma Y;  
 PI Zhao QA, Wang D, Wang J, Zhang J, Ren F, Chen R, Wang ZW;  
 PI Xue AJ, Yang Y, Wejhrman T, Goodrich R;

XX WPI: 2001-476283/51.  
 DR P-PSDB; AAM79104.

PT Nucleic acids encoding polypeptides with cytokine-like activities,  
 PT useful in diagnosis and gene therapy -

PS Claim 1; Page 2615-2616; 6221pp; English.

CC The invention relates to polynucleotides (AAK51456-AAK53435) and the  
 CC encoded polypeptides (AAM78923-AAH80302) that exhibit activity elating to  
 CC cytokine, cell proliferation or cell differentiation or which may induce  
 CC production of other cytokines in other cell populations. The  
 CC polynucleotides and polypeptides are useful in gene therapy, vaccines or  
 CC peptide therapy. The polypeptides have various cytokine-like activities,  
 CC e.g. stem cell growth factor activity, haematopoiesis regulating  
 CC activity, tissue growth factor activity, immunomodulatory activity and  
 CC activity/inhibin activity and may be useful in the diagnosis and/or  
 CC treatment of cancer, leukaemia, nervous system disorders, arthritis and  
 CC inflammation.  
 CC Note: Records for SEQ ID NO 2110 (AAK52581), 2111 (AAK52582) and 3666  
 CC (AAM80020) are omitted as the relevant pages from the sequence listing  
 CC were missing at the time of publication.

XX SQ Sequence 1312 BP; 370 A; 286 C; 287 G; 369 T; 0 other:

XX Alignment Scores:

Pred. No.: 2,19e-108 Length: 1312  
 Score: 1002.00 Matches: 190  
 Percent Similarity: 100.00% Conservative: 0  
 Best Local Similarity: 100.00% Mismatches: 0  
 Query Match: 100.00% Indels: 0  
 DB: 22 Gaps: 0

US-09-895-298a-83 (1-190) x AAK52237 (1-1312)

QY 1 MetMetAsnPhgInProProSerLysAlaTrpArgAlaSerGlnMetMetThrPhePhe 20  
 DB 294 ATGATGAATTTCCAGCCTCGAGCAAGCCTGGCGGCTCAGACAGATGACTTTCTTC 353  
 QY 21 IlePheLeuLeuPhePheProSerPheThrGlyValLeuCysThrLeuAlaIleThrIle 40  
 DB 354 ATCTTCTGCTCTTTTCCATCTTTCACCGGGGCTTGGACCTGGCCATCCACATC 413  
 QY 41 TrpArgLeuLysProSerAlaAspCysGlyProPheArgGlyLeuProLeuPheIleHis 60  
 DB 414 TGGAGATTAAGCCTTCAGCTGACTGTGGCCCTTTTCGAGCTGTGCTCTCATTCAC 473  
 QY 61 SerIleTySerTrpIleAspThrLeuSerThrArgProGlyTyrLeuTrpValValTrp 80  
 DB 474 TCCATGTACAGCTGATCCAGACCTTAAGTACACGGCTGGCTACCTGGGTGTGTTGG 533  
 QY 81 IleTyArgAsnLeuIleGlySerValHisPhePheIleLeuThrLeuIleValLeu 100  
 DB 534 ATCTATCGGAACCTCATTTGGAAGTGTGCACCTTCTTCATCTTCACCTCATTTGTGCTA 593  
 QY 101 IleIleThrTyrLeuTyrTrpGlnIleThrGlnGlyArgLysIleMetIleArgLeuLeu 120  
 DB 594 ATCATACCTATCTTACTGCGCAGATCACAGAGGAAGATTTTGATTAAGGCTGCTC 653  
 QY 121 HisGlnGlnIleIleAsnGlnGlyLysAspLysMetPheLeuIleGlnLysLeuIleLys 140

Db 654 CATGAGCATCATTAATGAGGCAAAAGATTAATGTTCCGTGATAGAGAAAATGTCATAG 713  
Qy 141 LeuGlnAspMetGluValysAlaAsnProSerSerLeuValLeuGluArgGluVal 160  
Db 714 CTGAGAGATATGAGGAAAGAAAGCAACCCAGCTCAGCTGTTCTGGAAGAGAGAGCTG 773  
Qy 161 GluGlnGlnGlyPheLeuHisLeuGlyGluHisAspGlySerLeuAspLeuArgSerArg 180  
Db 774 GAGCAACAAGGCTTTTTCATTTGGGGACATCATGCGACTCTTGACCTTCGATCTAGA 833  
Qy 181 ArgSerValGlnGlnGlyAsnProArgAla 190  
Db 834 AGATCAGTTCAAGAGGTAATCCAAGGCC 863

RESULT 5  
AAA78402  
ID AAA78402 standard; cDNA; 1461 BP.  
XX  
AC AAA78402:  
XX  
DT 20-NOV-2000 (first entry)  
XX  
DE Human secreted protein gene 22 SEQ ID NO:32.  
XX  
KW Human; secreted protein; cytostatic; antianaemic; antidiabetic;  
KW antiinflammatory; ophthalmological; antirheumatic; antidiabetic;  
KW antiparasitic; antianagenic; cardiant; anti-HIV; noctropic;  
KW neuroprotective; antimicrobial; antiparkinsonian; cancer;  
KW immune system disorder; angiogenesis; hyperproliferative disorder;  
KW cardiovascular disorder; apoptosis; neurological disease;  
KW infectious disease; wound healing; ss.  
XX  
OS Homo sapiens.  
XX  
PN NC0200035937-A1.  
XX  
PD 22-JUN-2000.  
XX  
PF 16-DEC-1999; 99WO-US29950.  
XX  
PR 17-DEC-1998; 98US-0112809.  
XX  
PR 18-DEC-1998; 98US-0113006.  
XX  
PA (HUMA-) HUMAN GENOME SCI INC.  
XX  
PI Ruben SM, Ebner R, Rosen CA, Endress GA, Soppet DR, Ni J;  
PI Dian DR, Moore PA, Shi Y, Lafleur DW, Olsen HS, Florence K;  
XX  
DR WPI: 2000-431566/37.  
DR P-PSDB: AAB24458.  
XX  
XX  
XX Forty seven human nucleic acids encoding secreted proteins, useful in  
XX the treatment, prevention and diagnosis of cancers, disorders of the  
XX immune system, angiogenesis disorders, neurological diseases and  
XX hyperproliferative disorders -  
XX  
XX Claim 1; Page 457-458; 562pp; English.  
XX  
XX The polynucleotide sequence given in AAA78381 to AAA78432 encode the  
XX human secreted proteins given in AAB24437 to AAB24604. Human secreted  
XX proteins have activities based on the tissues and cells the genes are  
XX expressed in. Examples of activities include: cytostatic; antianaemic;  
XX antidiabetic; antiinflammatory; ophthalmological; antirheumatic;  
XX antidiabetic; antiparasitic; antianagenic; cardiant; anti-HIV;  
XX noctropic; neuroprotective; antimicrobial and antiparkinsonian.  
XX Human secreted protein polynucleotides, polypeptides, antagonists and/or  
XX agonists may be useful in treating, preventing, and/or diagnosing other  
XX diseases, disorders, and/or conditions such as: (a) cancers; (b)  
XX disorders of the immune system; (c) angiogenesis disorders; (d)  
XX hyperproliferative disorders; (e) cardiovascular disorders; (f) diseases  
XX associated with increase apoptosis; (g) neurological diseases; and  
XX (h) infectious diseases. They are also used to promote wound healing.

CC AAA78372 to AAA78380 and AAB24436 represent sequences used in the  
CC exemplification of the present invention.  
XX  
SQ Sequence 1461 BP; 428 A; 312 C; 324 G; 397 T; 0 other;  
Alignment Scores:  
Pred. No.: 2,56e-108 Length: 1461  
Score: 1002.00 Matches: 190  
Percent Similarity: 100.00% Conservative: 0  
Best Local Similarity: 100.00% Mismatches: 0  
Query Match: 100.00% Indels: 0  
DB: 21 Gaps: 0

US-09-895-298a-83 (1-190) x AAA78402 (1-1461)

Qy 1 MetMetAspPheGlnProProSerLysAlaTrpArgAlaSerGlnMetMetThPhePhe 20  
Db 63 ATGATGAAATTTCCAGCCCTCCGAGCAAAAGCCGCGGGCTTCACAGATGATGACTTCTTC 122  
Qy 21 IlePheLeuLeuPhePheProSerPheThrGlyValLeuCysThrLeuAlaIleThrIle 40  
Db 123 ATCTTCTGCTCTTTTCCATCTTTCACCGGGGCTTGTGCACCTGGCCATCCACATC 182  
Qy 41 TrpArgLeuLysProSerAlaAspCysGlyProPheArgGlyLeuProLeuPheIleHis 60  
Db 183 TGGAGATTGAAGCCTTCAGCTGACGTGCGCCCTTTTCAGAGTCTGCTCTTCATTTCAC 242  
Qy 61 SerIleTySerTrpPheLeuAspThrLeuSerThrArgProGlyTyTrpValValTrp 80  
Db 243 TCCATCTACAGCTGGATGACACCCCTTAAGTACAGGCGCTGACTGCTGGGTTGTTGG 302  
Qy 81 IleTyArgAsnLeuIleGlySerValHisPhePheIleLeuThrLeuIleValLeu 100  
Db 303 ATCTATCGGAACCTCATGGAAGTGTGCATCTTTTCATCTACCTCATCTGTGTGCTA 362  
Qy 101 IleIleThrTyLeuTyTrpGlnIleThrGlnGlyArgLysIleMetIleArgLeuLeu 120  
Db 363 ATCATCACCTATCTTACTTGCGACATGCACAGAGGGAAGAAGATTATATAAGCTGCTC 422  
Qy 121 HisGlnGlnIleIleAsnGlnGlyLysAspLysMetPheLeuIleGlyLysLeuIleLys 140  
Db 423 CATGAGCATCATTAATGAGGCAAAAGATTAATGTTCTCTGATAGAAAATTTGATCAAG 482  
Qy 141 LeuGlnAspMetGluValysAlaAsnProSerSerLeuValLeuGluArgGluVal 160  
Db 483 CTGAGGATATGAGAGAAAGAAAGCAACCCAGCTCAGCTTGTGGAAGAGAGAGAGTG 542  
Qy 161 GluGlnGlnGlyPheLeuHisLeuGlyGluHisAspGlySerLeuAspLeuArgSerArg 180  
Db 543 GAGCAACAAGGCTTTTTCATTTGGGGACATCATGTCAGCTTGACCTTCGATCTAGA 602  
Qy 181 ArgSerValGlnGlnGlyAsnProArgAla 190  
Db 603 AGATCAGTTCAAGAGGTAATCCAAGGCC 632

RESULT 6  
AAH18131  
ID AAH18131 standard; cDNA; 1813 BP.  
XX  
XX  
XX AAH18131;  
XX  
XX 26-JUN-2001 (first entry)  
XX  
XX Human cDNA sequence SEQ ID NO:18001.  
XX  
XX Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.  
XX  
XX Homo sapiens.  
XX  
XX EP1074617-A2.  
XX  
XX 07-FEB-2001.  
XX

PF 28-JUL-2000; 2000EP-0116126.  
 XX  
 PR 29-JUL-1999; 99JP-0248036.  
 PR 27-AUG-1999; 99JP-0300253.  
 PR 11-JAN-2000; 2000JP-0118776.  
 PR 02-MAY-2000; 2000JP-0183767.  
 PR 09-JUN-2000; 2000JP-0241899.  
 XX  
 PA (HELI-) HELIX RES INST.  
 PI Ota T, Isegai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;  
 PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;  
 DR WPI; 2001-318749/34.  
 XX  
 PT Primer sets for synthesizing polynucleotides, particularly the 5602  
 PT full-length cDNAs defined in the specification, and for the detection  
 PT and/or diagnosis of the abnormality of the proteins encoded by the  
 PT full-length cDNAs -  
 PS  
 PS Claim 8: SEQ ID 18001; 2537bp + CD ROW; English.  
 XX  
 CC The present invention describes primer sets for synthesizing 5602  
 CC full-length cDNAs defined in the specification. Where a primer set  
 CC comprises: (a) an oligo-dT primer and an oligonucleotide complementary  
 CC to the complementary strand of a polynucleotide which comprises one of  
 CC the 5602 nucleotide sequences defined in the specification, where the  
 CC oligonucleotide comprises at least 15 nucleotides; or (b) a combination  
 CC of an oligonucleotide comprising a sequence complementary to the  
 CC complementary strand of a polynucleotide which comprises a 5'-end  
 CC sequence and an oligonucleotide comprising a sequence complementary to a  
 CC polynucleotide which comprises a 3'-end sequence, where the  
 CC oligonucleotide comprises at least 15 nucleotides and the combination of  
 CC the 5'-end sequence/3'-end sequence is selected from those defined in  
 CC the specification. The primer sets can be used in antisense therapy and  
 CC in gene therapy. The primers are useful for synthesizing polynucleotides,  
 CC particularly full-length cDNAs. The primers are also useful for the  
 CC detection and/or diagnosis of the abnormality of the proteins encoded by  
 CC the full-length cDNAs. The primers allow obtaining of the full-length  
 CC cDNAs easily without any specialised methods. AAH03166 to AAH13628 and  
 CC AAH13633 to AAH18742 represent human cDNA sequences; AAB92446 to  
 CC AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632  
 CC represent oligonucleotides, all of which are used in the exemplification  
 CC of the present invention.  
 CC  
 SQ Sequence 1813 BP; 489 A; 400 C; 405 G; 519 T; 0 other;  
 XX  
 Alignment Scores:  
 Pred. No.: 3.5e-108 Length: 1813  
 Score: 1002.00 Matches: 190  
 Percent Similarity: 100.00% Conservative: 0  
 Best Local Similarity: 100.00% Mismatches: 0  
 Query Match: 100.00% Indels: 0  
 DB: 22 Gaps: 0  
 US-09-895-298A-83 (1-190) x AAH18131 (1-1813)  
 QY 1 MetMetAsnPhgInpProSerIysAlaTrpArgAlaSerGlnMetMetRhpPhe 20  
 DB 451 ATGATGAAATTTCCAGCCTCCGAGCAAGCCTGCGGCTCAGACAGATGACTTCTTC 510  
 QY 21 IlePheLeuLeuPhePheProSerPheThrGlyValLeuCysThrLeuAlaIlePhe 40  
 DB 511 AACTCTCTCTCTTTTCCATCCTTACCGGGGTCTTGACACCTGGCCATCACATC 570  
 QY 41 TrpArgLeuLysProSerAlaAspCysGlyProPheArgGlyLeuProLeuPheIleHis 60  
 DB 571 TCGAGATTGAAAGCCTTCACCTGCTGCGCCTTTTCGAGGCTGCTCTTCATTCAC 630  
 QY 61 SerIleTySerTrpIleAspThrLeuSerThrArgProGlyTyrLeuTrpValValTrp 80  
 DB 631 TCCATCTACAGCTGAGTGCACACCCCTAACTACACGGCCTGCTGCTGCTGCTGCTG 690

QY 81 IleTyrArgAsnLeuIleGlySerValHisPhePheIleLeuThrLeuIleValLeu 100  
 DB 691 AACTATCGGAACCTCATTTGGAAGTGTGCACCTCTTTTATCCTCACCCTCATTTGTGCTA 750  
 QY 101 IleIleThrTyrLeuTyrTrpGlnIleThrGlnGlyArgLysIleMetIleArgLeuLeu 120  
 DB 751 ATCATCACCCTATCTTACGTGGCAGATCACAGAGGAGGAAGATTTATGATTAAGCTGCTC 810  
 QY 121 HisGlnGlnIleIleAsnGlnGlyLysAspLysMetPheLeuIleGlnLysLeuIleLys 140  
 DB 811 CATGACACATCATTTATATGAGGCGCAAGATTAATTTCTCTGATATGAAAAATTGATCAAG 870  
 QY 141 LeuGlnAspMetGlnLysLysAlaAsnProSerSerLeuValLeuGlnArgArgGluVal 160  
 DB 871 CTCGACGATATGGAAGAAGCAACCCAGCTCCTGTTCTGAAAGAGAGAGTG 930  
 QY 161 GlnGlnGlnGlnGlyPheLeuHisLeuGlyGluHisAspCysSerLeuAspLeuArgSerArg 180  
 DB 931 GAGCAACAAGGCTTTTGGATTTGGGGGGAACATGATGGCAGTCTGATTCGATCTAGA 990  
 QY 181 ArgSerValGlnGlnGlyAsnProArgAla 190  
 DB 991 ACATCAGTTCAAGACGTAATCCAAAGGCC 1020  
 RESULT 7  
 ID AAF82462 standard; cDNA; 1960 BP.  
 XX AAF82462:  
 AC AAF82462:  
 XX  
 DT 29-JUN-2001 (first entry)  
 XX  
 DE Human CASB6411-related cDNA #1.  
 XX  
 KW Human; CASB6411; vaccine; gene therapy; immunoprophylaxis;  
 KW ovarian cancer; colon cancer; autoimmune disease; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 FH Key location/Qualifiers  
 FT CDS 1..1317  
 FT /\*tag= a  
 FT /partial  
 FT /note= "this sequence does not contain a start codon"  
 XX  
 PN MO200123417-A2.  
 XX  
 PD 05-APR-2001.  
 XX  
 PF 27-SEP-2000; 2000WO-EP09500.  
 XX  
 PR 30-SEP-1999; 99GB-0023154.  
 PR 07-JUL-2000; 2000GB-0016839.  
 XX  
 PA (SMRK ) SMITHKLINE BEECHAM BIOLOGICALS.  
 PI Vinals De Bassols YC;  
 PI WPI; 2001-316133/33.  
 DR P-PSDB; AAB83081.  
 XX  
 PT Novel CASB6411 polypeptides useful in diagnostics, and as vaccines for  
 PT prophylactic and therapeutic treatment of cancers, particularly ovarian  
 PT and colon cancers, autoimmune diseases and related conditions -  
 XX  
 PS Claim 32; Page 65-66; 95pp; English.  
 XX  
 CC The present sequence is provided in a specification relating  
 CC to CASB6411 polypeptides comprising a sequence having at least 70%  
 CC identity to a sequence of 460 or 154 amino acids fully defined in  
 CC the specification. CASB6411 polypeptides and polynucleotides are  
 CC useful for treating a subject by immunoprophylaxis or therapy.  
 CC The CASB6411 polypeptides are useful in diagnostics, and as





```
Db 760 ATCTTCGTCTCTTTTCCATCCCTTACCGGGGCTCTTGACCCCTGGCCATCACCATC 819
Qy 41 TTPArgLeuLysProSerAlaAspCysGlyProPheArgGlyLeuProLeuPheIleHis 60
Db 820 TGGAGATTGAAAGCTTCAGCTGACTGTGGCCCTTTTCGAGAGTCTGCTCTTCATTCAC 879
Qy 61 SerIleTyrSerTrpIleAspThrLeuSerThrArgProGlyTyrLeuTrpValVal 80
Db 880 TCCATCTACAGCTGGATGACACCCCTAAGTACACAGGCGCTGCTGCTGCTGCTGCTGCTG 939
Qy 81 IleTyrArgAsnLeuIleGlySerValHisPhePhePheIleLeuThrLeuIleValLeu 100
Db 940 ATCTATCGGAACCTCATTTGGAAGTGTGCACTTCTTTTCACTCCACCCCTCATTTGTCTA 999
Qy 101 IleIleThrTyrLeuTyrTrpGlnIleThrGlnGlyArgGlyIleMetIleArgLeuLeu 120
Db 1000 ATCATCACCATTCTTACTGCGCATCAGACGAGGAAAGATTATGATGAAGGCTGCTC 1059
Qy 121 HisGlnGlnIleIleAsnGlyLysAspLysMetPheLeuIleGlyLysLeuIleLys 140
Db 1060 CATGACGACAGATCATTAATGAGGCAAAAGATAAATGTTCTGTATGAAAAATGATCAAG 1119
Qy 141 LeuGlnAspMetGlyLysLysAlaAsnProSerSerLeuValLeuGlnArgGlnVal 160
Db 1120 CTGCAGGATATGAGAGAAAGCAACCCCACTCCTGCTGCTGCTGCTGCTGCTGCTG 1179
Qy 161 GluGlnGlnIleLeuAsnGlyLysAlaAspGlySerLeuAspLeuArgSerArg 180
Db 1180 GAGCAACAAAGCTTTTTCATTTGGGAGAACATGATGCGAGTCTTGACTTGCGATCTAGA 1239
Qy 181 ArgSerValGlnGlnGlyLysAsnProArgAla 190
Db 1240 AGATCAGTTCAAGAGATATCAAGGGCC 1269
RESULT 9
AAf82460
ID AAF82460 standard; cDNA; 2407 BP.
XX
AC AAF82460;
XX
DT 29-JUN-2001 (first entry)
XX
DE Human CASB6411 cDNA.
XX
KW Human; CASB6411; vaccine; gene therapy; immunoprophylaxis;
KW ovarian cancer; colon cancer; autoimmune disease; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 382..1764
FT /tag= a
FT /product= "CASB6411"
XX
PN WO200123417-A2.
XX
PD 05-APR-2001.
XX
PF 27-SEP-2000; 2000MO-EP09500.
XX
PR 30-SEP-1999; 99GB-0023154.
PR 07-JUL-2000; 2000GB-0016839.
XX
PA (SMK ) SMITHKLINE BEECHAM BIOLOGICALS.
PI Vinals De Bassols YC;
XX
DR WPI; 2001-316133/33.
DR P-PSDB; AAB83079.
XX
PT Novel CASB6411 polypeptides useful in diagnostics, and as vaccines for
PT prophylactic and therapeutic treatment of cancers, particularly ovarian
PT and colon cancers, autoimmune diseases and related conditions
```

```
XX
PS Claim 11; Page 63-64; 95pp; English.
XX
CC The present sequence encodes human CASB6411 polypeptide. The
CC invention relates to CASB6411 polypeptides comprising a sequence
CC having at least 70% identity to a sequence of 460 or 154 amino acids
CC fully defined in the specification. CASB6411 polypeptides and
CC polynucleotides are useful for treating a subject by immunoprophylaxis
CC or therapy. The CASB6411 polypeptides are useful in diagnostics, and
CC as vaccines for prophylactic and therapeutic treatment of cancers,
CC particularly ovarian and colon cancers, autoimmune diseases and related
CC conditions. CASB6411 polypeptides are also useful for the
CC structure-based design of agonists, antagonists or inhibitors of the
CC polypeptide. The present sequence may be alternatively spliced to
CC generate a sequence encoding a truncated CASB6411 protein.
XX
SQ Sequence 2407 BP; 635 A; 557 C; 546 G; 669 T; 0 other;

Alignment Scores:
Pred. No.: 5,26e-108 Length: 2407
Score: 1002.00 Matches: 190
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: Gaps: 0

US-09-895-298A-83 (1-190) x AAF82460 (1-2407)
Qy 1 MetMetAsnPheGlnProProSerLysAlaTrpArgAlaSerGlnMetThrPhePhe 20
Db 1192 ATGATAAATTTCCAGCCTCGAGCAAAAGCTGGGGCCCTCAAGATGATGACTTCTTC 1251
Qy 21 IlePheLeuLeuPhePhePheProSerPheThrGlyValLeuGlySerThrLeuAlaIleTrp 40
Db 1252 ATCTTCTGCTCTTTTCCATCTTCACCGGGGCTGTGTGACCCCTGGCATCACCATC 1311
Qy 41 TTPArgLeuLysProSerAlaAspCysGlyProPheArgGlyLeuProLeuPheIleHis 60
Db 1312 TGGAGATTGAAAGCTTCAGCTGACTGTGGCCCTTTTCAGAGTCTGCTCTTCATTCAC 1371
Qy 61 SerIleTyrSerTrpIleAspThrLeuSerThrArgProGlyTyrLeuTrpValVal 80
Db 1372 TCCATCTACAGCTGGATGACACCCCTAAGTACACGGGCTGCTACCTGTGGATTGTTGG 1431
Qy 81 IleTyrArgAsnLeuIleGlySerValHisPhePhePheIleLeuThrLeuIleValLeu 100
Db 1432 ATCTATCGGAACCTCATTTGGAAGTGTGCACTTCTTTTCACTCCACCCCTCATTTGTCTA 1491
Qy 101 IleIleThrTyrLeuTyrTrpGlnIleThrGlnGlyArgGlyIleMetIleArgLeuLeu 120
Db 1492 ATCATCACCATTCTTACTGCGCATCAGACGAGGAAAGATTATGATGAAGGCTGCTC 1551
Qy 121 HisGlnGlnIleIleAsnGlyLysAspLysMetPheLeuIleGlyLysLeuIleLys 140
Db 1552 CATGACGACATCATTAATGAGGCAAAAGATAAATGTTCTGTATGAAAAATGATCAAG 1611
Qy 141 LeuGlnAspMetGlyLysLysAlaAsnProSerSerLeuValLeuGlnArgGlnVal 160
Db 1612 CTGCAGGATATGAGAGAAAGCAACCCCACTCCTTCTTGGAAGGAGAGAGGTG 1671
Qy 161 GluGlnGlnIleLeuAsnGlyLysAlaAspGlySerLeuAspLeuArgSerArg 180
Db 1672 GAGCAACAAAGCTTTTTCATTTGGGAGAACATGATGCGAGTCTTGACTTGCGATCTAGA 1731
Qy 181 ArgSerValGlnGlnGlyLysAsnProArgAla 190
Db 1732 AGATCAGTTCAAGAGTATATCAAGGGCC 1761
RESULT 10
AAf82461
ID AAF82461 standard; cDNA; 2521 BP.
XX
AC AAF82461;
```

```

XX 29-JUN-2001 (first entry)
XX
XX Alternatively spliced human CASB6411 cDNA encoding truncated protein.
XX
XX DE
XX
XX
XX Human; CASB6411; vaccine; gene therapy; immunoprophylaxis;
XX ovarian cancer; colon cancer; autoimmune disease; isoform;
XX alternative splicing; ss.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX CDS 382..846
XX FT /*tag= a
XX FT /product= "truncated CASB6411"
XX
XX WO200123417-A2.
XX
XX PD 05-APR-2001.
XX
XX PF 27-SEP-2000; 2000WO-EP09500.
XX
XX PR 30-SEP-1999; 99GB-0023154.
XX PR 07-JUL-2000; 2000GB-0016839.
XX
XX (SMK ) SMITHKLINE BEECHAM BIOLOGICALS.
XX
XX Vlnals De Bassols YC;
XX
XX PI WPI: 2001-316133/33.
XX DR P-PSDB: AAB83080.
XX
XX Novel CASB6411 polypeptides useful in diagnostics, and as vaccines for
XX prophylactic and therapeutic treatment of cancers, particularly ovarian
XX and colon cancers, autoimmune diseases and related conditions
XX
XX Claim 11; Page 64-65; 95pp; English.
XX
XX
XX The present sequence encodes a truncated CASB6411 polypeptide. It
XX is generated by alternative splicing of the full length human cDNA
XX sequence of CASB6411. The invention relates to CASB6411 polypeptides
XX comprising a sequence having at least 70% identity to a sequence of
XX 460 or 154 amino acids fully defined in the specification. CASB6411
XX polypeptides and polynucleotides are useful for treating a subject by
XX immunoprophylaxis or therapy. The CASB6411 polypeptides are useful in
XX diagnostics, and as vaccines for prophylactic and therapeutic treatment
XX of cancers, particularly ovarian and colon cancers, autoimmune diseases
XX and related conditions. CASB6411 polypeptides are also useful for the
XX structure-based design of agonists, antagonists or inhibitors of the
XX polypeptide.
XX
XX SQ Sequence 2521 BP; 662 A; 583 C; 583 G; 693 T; 0 other;
XX
XX Alignment Scores:
XX Pred. No.: 5.62e-108 Length: 2521
XX Score: 1002.00 Matches: 190
XX Percent Similarity: 100.00% Conservative: 0
XX Best Local Similarity: 100.00% Mismatches: 0
XX Query Match: 100.00% Indels: 0
XX Gaps: 0
XX
XX US-09-895-298A-83 (1-190) x AAF82461 (1-2521)
XX
XX 1 MetMetAspNheGlnProProSerLeuYsaIaTtPARGAlaSerGlnMetMetThrpPhe 20
Db 1306 ATGATGATTTCCAGCCTCCAGCAAGCGTGGCGGCTCCACAGATGATGACTTTCTTC 1365
XX
XX 21 IlePheLeuLeuPheProSerPheThrGlyValLeuCYsThrLeuAlaIleThrIle 40
Db 1366 ATCTTCTTGCTCTTTTCCATCTTACCGGGGCTTGTGACACCGTGGCATCACCATC 1425
XX
XX 41 TTPArgLeuLysProSerAlaLysPcySgLyProPheArgGlyLeuProLeuPheIleHis 60
XX

```

Db	1426	TGGAGATTGAAGCCTTCACCTGACTGACTGCTGGGCCCTTTTCAGAGTGTGGCTCTCTTCATTTCAC	1485
Qy	61	SerIleTyrSerTrpIleAspThrLeuSerThrArgProGlyTyrLeuTrpValValTrp	80
Db	1486	TCCATCTACAGCTGGATGCATGCACACCCATAAGTACACGGCCCTGGTACCTGTGGTGTGGTGG	1545
Qy	81	IleTyrArgAsnLeuIleGlySerValHisPhePhePheIleLeuThrLeuIleValLeu	100
Db	1546	ATCTATCGGAACCTCATTTGGAAAGTGACACTTCTTTTTCATCTCCACCCCTCATTTGTCTA	1605
Qy	101	IleIleThrTyrLeuTyrTrpGlnIleThrGlnGlyValArgLysIleMetIleArgLeuLeu	120
Db	1606	ATCATCACTTACTTCTTACTGCGCAGATCACAGAGGGAAGAGATTATGATAAGGCTCTC	1665
Qy	121	HisGlnGlnIleIleAsnGlnGlyLysAspLysMetPheLeuIleGlyLysLeuLys	140
Db	1666	CATGACGACATCATTTATATGAGGGCAAAAGATAAATGCTCTCATAGAAAAATTGATCAAG	1725
Qy	141	LeuGlnAspMetGlyLysLysAlaAsnProSerSerLeuValIleuGlnArgGlnVal	160
Db	1726	CTGCAGAGATATGGAGAGAAAGCAAAACCCAGCTCACTGTTCGTGGAAAGAGAGAGGTG	1785
Qy	161	GlnGlnGlnGlnGlyPheLeuHisLeuGlyGluHisAspGlySerLeuAspLeuArgSerArg	180
Db	1786	GAGCAACAAGGCTTTTTCGATTTTGGGGGGAACATGATGCGCAGTCTTGACTTCCGATCTAGA	1845
Qy	181	ArgSerValGlnGlnGlnGlyAsnProArgAla	190
Db	1846	AGATCAGTTCAAGAAAGTATATCCAAAGGCC	1875
RESULT 11			
ABV22463			
ID	ABV22463	standard; CDNA; 1194 BP.	
XX	AC	ABV22463;	
XX	DT	13-SEP-2002 (first entry)	
XX	DE	Human prostate expression marker CDNA 22454.	
XX	KW	Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;	
XX	KM	pharmacogenomic marker; gene; ss.	
OS	OS	Homo sapiens.	
XX	PN	WO200160860-A2.	
XX	PD	23-AUG-2001.	
XX	PF	20-FEB-2001; 2001WO-US05171.	
XX	PR	17-FEB-2000; 2000US-183319P.	
XX	PR	16-MAR-2000; 2000US-189862P.	
XX	PR	25-MAY-2000; 2000US-207454P.	
XX	PR	09-JUN-2000; 2000US-211314P.	
XX	PR	18-JUL-2000; 2000US-219007P.	
XX	PR	13-DEC-2000; 2000US-255281P.	
PA	(MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.		
XX	PI	Schlegel R, Endege WO, Monahan JE;	
XX	DR	WPI; 2001-662795/76.	
PT	Novel isolated nucleic acid molecule associated with cancerous state of		
PT	prostate cells and correlating with presence of prostate cancer, useful		
PT	for detecting presence of prostate cancer, stage of prostate cancer -		
PS	Claim 1; Page 3912; 11750p; English.		
XX	The invention relates to an isolated nucleic acid molecule (I) comprising		
CC	a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the		
CC	specification or its complement. (I) is useful for:		

CC (a) assessing whether a patient is afflicted with prostate cancer;  
CC (b) monitoring the progression of prostate cancer in a patient;  
CC (c) assessing the efficacy of a test compound to inhibit prostate  
CC cancer in a patient;  
CC (d) assessing the efficacy of a therapy for inhibiting prostate cancer  
CC in a patient;  
CC (e) selecting a composition for inhibiting prostate cancer in a patient;  
CC (f) assessing the prostate cell carcinogenic potential of a compound;  
CC (g) determining whether prostate cancer has metastasized in a patient;  
CC (h) assessing the aggressiveness or indolence of prostate cancer in a  
CC patient;  
CC (I) is also useful as a pharmacodynamic or pharmacogenomic marker.  
XX  
XX  
SQ Sequence 1194 BP; 288 A; 287 C; 278 G; 339 T; 2 other;  
  
Alignment Scores:  
Pred. No.: 1,19e-102 Length: 1194  
Score: 953.00 Matches: 186  
Percent Similarity: 97.89% Conservative: 0  
Best Local Similarity: 97.89% Mismatches: 4  
Query Match: 95.11% Indels: 1  
DB: 23 Gaps: 0  
  
US-09-895-298a-83 (1-190) x ABV22463 (1-1194)  
QY 1 MetMetAsnPhneGlnProProSerLysAlaTPArgAlaSerGlnMetMetThrPhePhe 20  
DB 531 ATGATGAATTTCCAGCCTCGAGCAAAAGCCTGGCGGCTCCACAGATGATGATCTTCTC 590  
QY 21 IlePheLeuLeuPhePheProSerPheThrGlyValLeuGlyThrLeuAlaIleThrIle 40  
DB 591 ATCTTCTCTCTTTTCCATCTTCACCGGGGCTTGTCACCTGGCCATCCACCATC 650  
QY 41 TPArgLeuLysProSerAlaAspCysGlyProPheArgGlyLeuProLeuPheIleHis 60  
DB 651 TGGAGATTGAAGCCTTCACGCTGACTGTGGCCCTTTTCGAGGTGGCTCTCTTCATTCAC 710  
QY 61 SerIleTySerTrpIleAspThrLeuSerThrArgProGlyTyLeuTrpValValTrp 80  
DB 711 TCATCTACAGCTGATGACGACCCCTAAGTACACAGCGCTGGTACTGCTGGTGTGG 770  
QY 81 IleTyArgAsnLeuLeuGlySerValHisPhePheIleLeuThrLeuIleValLeu 100  
DB 771 ATCTATCGGAACCTCATGTGAAAGTGACCTCTTTTCACTCCACCTCATTTGCTA 830  
QY 101 IleIleThrTyLeuTyTrpGlnIleThrGlnGlyArgGlyIleMetIleArgLeuLeu 120  
DB 831 ATCATCACTATCTTACTGCGCATCAGACAGAGGAAGATTTATGATTAAGGCTGCTC 890  
QY 121 HisGlnGlnIleIleAsnGlnGlyLysAspLysMetPheLeuIleGlnLysLeuIleLys 140  
DB 891 CATGACACAGATCATTAATGAGGCAAAAGATAAATGTTCTCTGATAGAAAATGATCAAG 950  
QY 141 LeuGlnAspMetGlnLysLysAlaAsnProSerSerLeuValLeuGlnArgGlnVal 160  
DB 951 CTGACAGAAATGAGAAAGAAACCAACCCAGC-TCACCTGTACTGAAAAGAGAGAGG 1009  
QY 161 GlnGlnGlnGlyPheLeuHisLeuGlnGlyLysAspGlySerLeuAspLeuArgSerArg 180  
DB 1010 GAGCAACAAAGGCTTATTTGCTTAGCGGAGACATGATGCGACTTGTGCACTCTAGA 1069  
QY 181 ArgSerValGlnGlnGlnLysAsnProArgAla 190  
DB 1070 CGATCAGTTCAAGAAAGTAAATCCAAAGGCC 1099  
  
RESULT 12  
ABV25683  
ID ABV25683 standard; cDNA; 1194 BP.  
XX  
XX  
AC ABV25683;  
XX  
XX  
DT 16-SEP-2002 (first entry)  
XX

DE Human prostate expression marker CDNA 25574.  
XX  
XX Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;  
KW pharmacogenomic marker; gene; ss.  
XX  
XX Homo sapiens.  
XX  
XX WO200160860-A2.  
XX  
XX 23-AUG-2001.  
XX  
XX 20-FEB-2001; 2001WO-US05171.  
XX  
XX 17-FEB-2000; 2000US-183319P.  
XX 16-MAR-2000; 2000US-189862P.  
XX 25-MAY-2000; 2000US-207454P.  
XX 09-JUN-2000; 2000US-211314P.  
XX 18-JUL-2000; 2000US-219007P.  
XX 13-DEC-2000; 2000US-255281P.  
XX  
XX (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.  
XX  
XX Schlegel R, Endege WO, Monahan JE;  
XX  
XX WPI: 2001-662795/76.  
XX  
XX Novel isolated nucleic acid molecule associated with cancerous state of  
XX prostate cells and correlating with presence of prostate cancer; useful  
XX for detecting presence of prostate cancer; stage of prostate cancer -  
XX  
XX Claim 1; Page 5146-5147; 11750pp; English.  
XX  
XX The invention relates to an isolated nucleic acid molecule (I) comprising  
XX a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the  
XX specification or its complement. (I) is useful for:  
XX (a) assessing whether a patient is afflicted with prostate cancer;  
XX (b) monitoring the progression of prostate cancer in a patient;  
XX (c) assessing the efficacy of a test compound to inhibit prostate  
XX cancer in a patient;  
XX (d) assessing the efficacy of a therapy for inhibiting prostate cancer  
XX in a patient;  
XX (e) selecting a composition for inhibiting prostate cancer in a patient;  
XX (f) assessing the prostate cell carcinogenic potential of a compound;  
XX (g) determining whether prostate cancer has metastasized in a patient;  
XX (h) assessing the aggressiveness or indolence of prostate cancer in a  
XX patient;  
XX (I) is also useful as a pharmacodynamic or pharmacogenomic marker.  
XX  
XX Sequence 1194 BP; 288 A; 287 C; 278 G; 339 T; 2 other;  
SQ  
  
Alignment Scores:  
Pred. No.: 1,19e-102 Length: 1194  
Score: 953.00 Matches: 186  
Percent Similarity: 97.89% Conservative: 0  
Best Local Similarity: 97.89% Mismatches: 4  
Query Match: 95.11% Indels: 1  
DB: 23 Gaps: 0  
  
US-09-895-298a-83 (1-190) x ABV25683 (1-1194)  
QY 1 MetMetAsnPhneGlnProProSerLysAlaTPArgAlaSerGlnMetMetThrPhePhe 20  
DB 531 ATGATGAATTTCCAGCCTCGAGCAAAAGCCTGGCGGCTCCACAGATGATGATCTTCTC 590  
QY 21 IlePheLeuLeuPhePheProSerPheThrGlyValLeuGlyThrLeuAlaIleThrIle 40  
DB 591 ATCTTCTCTCTTTTCCATCTTCACCGGGGCTTGTCACCTGGCCATCCACCATC 650  
QY 41 TPArgLeuLysProSerAlaAspCysGlyProPheArgGlyLeuProLeuPheIleHis 60  
DB 651 TGGAGATTGAAGCCTTCACGCTGACTGTGGCCCTTTTCGAGGTGGCTCTCTTCATTCAC 710  
QY 61 SerIleTySerTrpIleAspThrLeuSerThrArgProGlyTyLeuTrpValValTrp 80

```

|||||
Db 711 TCACATCTACAGCTGGATGACACCCTAAGTACACGGCCTGGCTGACTGCTGTTGTTGG 770
Qy 81 IletyTArGAsnLeuIleGlySerValHisPhePhePheIleuThleuIleValleu 100
Db 771 ATCTATCGGAACCTCATTTGGAAGTGTGCACCTCTTTTCATCCACCCCTCATTTGTGCTA 830
Qy 101 IletleThrTyTleuTyTTrpGlnIleThrGluGluYArGlySileMetIleArgleuIleu 120
Db 831 ATCATCACCCTTCTTTACTGCAATCCACAGAGGGAAGAGATTATATATAGGCTGCTC 890
Qy 121 HisGluGlnIleIleAsnGluGlyLysAspLysMetPheleuIleGlyLysleuIlelys 140
Db 891 CATGAGCAGATCATTAATAGAGGCAAGATAAATGTTCTGATAGAAAATTTGATCAAG 950
Qy 141 LeuGlnAspMetGluLysLysAlaAsnProSerSerleuValleuGluYArGluVal 160
Db 951 CTGCAGGATATGAGAAAGAAAGCAACCCAGC-TCACCTTGTACTGGAAAGAGAGAGCTG 1009
Qy 161 GluGlnGlnGlyPheleuHisLeuGlyGluHisAspGlySerleuAspLeuArgSerArg 180
Db 1010 GAGCAACAAGCCTTATTCATTTAGCGGACATGATGCGACTTGTGACTTGCATCTAGA 1069
Qy 181 ArgSerValGlnGluGlyAsnProArgAla 190
Db 1070 CGATCAGTTCAAGAAGTAATCCAAGGCC 1099

RESULT 13
ABV28278
ID ABV28278 standard; cDNA; 1194 BP.
XX
AC ABV28278;
XX
DT 16-SEP-2002 (first entry)
XX
De Human prostate expression marker cDNA 28269.
XX
KW Human prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;
KW pharmacogenomic marker; gene; ss.
XX
OS Homo sapiens.
XX
PN MO200160860-A2.
PD 23-AUG-2001.
XX
PF 20-FEB-2001; 2001WO-US05171.
XX
PR 17-FEB-2000; 2000US-183319P.
PR 16-MAR-2000; 2000US-189862P.
PR 25-MAY-2000; 2000US-207454P.
PR 09-JUN-2000; 2000US-211314P.
PR 18-JUL-2000; 2000US-219007P.
PR 13-DEC-2000; 2000US-255281P.
XX
PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX
PI Schlegel R, Endege WO, Monahan JE;
XX
WPI; 2001-662795/76.
XX
PT Novel isolated nucleic acid molecule associated with cancerous state of
PT prostate cells and correlating with presence of prostate cancer, useful
PT for detecting presence of prostate cancer, stage of prostate cancer -
XX
PS Claim 1; Page 5881-5882; 11750pp; English.
XX
XX The invention relates to an isolated nucleic acid molecule (I) comprising
XX a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the
XX specification or its complement. (I) is useful for:
XX (a) assessing whether a patient is afflicted with prostate cancer;
XX (b) monitoring the progression of prostate cancer in a patient;
XX (c) assessing the efficacy of a test compound to inhibit prostate

```

```

CC cancer in a patient;
CC (d) assessing the efficacy of a therapy for inhibiting prostate cancer
CC in a patient;
CC (e) selecting a composition for inhibiting prostate cancer in a patient;
CC (f) assessing the prostate cell carcinogenic potential of a compound;
CC (g) determining whether prostate cancer has metastasized in a patient;
CC (h) assessing the aggressiveness or indolence of prostate cancer in a
CC patient;
CC (i) is also useful as a pharmacodynamic or pharmacogenomic marker.
XX
SQ Sequence 1194 BP; 288 A; 287 C; 278 G; 339 T; 2 other:
XX
Alignment Scores:
Pred. No.: 1,19e-102 Length: 1194
Score: 953.00 Matches: 186
Percent Similarity: 97.89% Conservative: 0
Best Local Similarity: 97.89% Mismatches: 4
Query Match: 95.11% Indels: 1
DB: Gaps: 0
US-09-895-298a-83 (1-190) x ABV28278 (1-1194)
Qy 1 MetMetAsnPhenGlnProProSerLysAlaTrpArgAlaSerGlnMetMetThPhePhe 20
Db 531 ATGATGAAATTTCCAGCCTCCGAGCAAGCCTGGGGGCTCCACAGATGATGACTTCTTC 590
Qy 21 IlePheLeuLeuPhePheProSerPheThrGlyValleuCysThrLeuAlaIleThrIle 40
Db 591 ATCTTCTTGCCTCTTTTCCATCCCTTCACCGGGGCTTGTGCACCCCTGACCATCCATC 650
Qy 41 TrpArgLeuLysProSerAlaAspCysGlyProPheArgGlyLeuProLeuPheIleHis 60
Db 651 TGGAGATTGAAGCCTTCACTGACTGCTGCCCCCTTTTTCAGAGGTGCTCCTCTTCAATTAC 710
Qy 61 SerIleYSerTrpIleAspThrLeuSerThrArgProGlyTyTleuTrpValValTrp 80
Db 711 TCACATCTACAGCTGGATGACACCCCTAGTACAGGCGCTGGCTGAGGTTGTTGG 770
Qy 81 IletyTArGAsnLeuIleGlySerValHisPhePhePheIleuThleuIleValleu 100
Db 771 ATCTATCGGAACCTCATTTGGAAGTGTGCACCTCTTTTCATCCACCCCTCATTTGTGCTA 830
Qy 101 IletleThrTyTleuTyTTrpGlnIleThrGluGluYArGlySileMetIleArgleuIleu 120
Db 831 ATCATCACCCTTCTTTACTGCAATCCACAGAGGGAAGAGATTATATATAGGCTGCTC 890
Qy 121 HisGluGlnIleIleAsnGluGlyLysAspLysMetPheleuIleGlyLysleuIlelys 140
Db 891 CATGAGCAGATCATTAATAGAGGCAAGATAAATGTTCTGATAGAAAATTTGATCAAG 950
Qy 141 LeuGlnAspMetGluLysLysAlaAsnProSerSerleuValleuGluYArGluVal 160
Db 951 CTGCAGGATATGAGAAAGAAAGCAACCCAGC-TCACCTTGTACTGGAAAGAGAGAGCTG 1009
Qy 161 GluGlnGlnGlyPheleuHisLeuGlyGluHisAspGlySerleuAspLeuArgSerArg 180
Db 1010 GAGCAACAAGCCTTATTCATTTAGCGGACATGATGCGACTTGTGACTTGCATCTAGA 1069
Qy 181 ArgSerValGlnGluGlyAsnProArgAla 190
Db 1070 CGATCAGTTCAAGAAGTAATCCAAGGCC 1099

RESULT 14
AAL18591
ID AAL18591 standard; cDNA; 470 BP.
XX
AC AAL18591;
XX
DT 07-DEC-2001 (first entry)
XX
De Human breast cancer expressed polynucleotide 11048.
XX
KW Human; breast cancer; cell marker; cytostatic; ss.

```

```

XX OS Homo sapiens.
XX PN WO200151628-A2.
XX PD 19-JUL-2001.
XX PF 10-JAN-2001; 2001WO-US00798.
XX PR 14-JAN-2000; 2000US-0176077.
XX PR 14-MAR-2000; 2000US-0189167.
XX PR 24-MAR-2000; 2000US-0192099.
XX PR 29-MAR-2000; 2000US-0193480.
XX PR 15-MAY-2000; 2000US-0205230.
XX PR 09-JUN-2000; 2000US-0211315.
XX PR 25-JUL-2000; 2000US-0220534.
XX PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX PI Lillie J, Xu Y, Wang Y, Steinmann K;
XX DR WPI; 2001-451856/48.
XX PT New peptide useful as a marker for the diagnosis of breast cancer -
XX PS Claim 1; Page 1968; 3695pp; English.
XX CC The invention relates to human breast cancer expressed polynucleotides
CC (AAU07544-AAU6789) and methods of assessing whether a patient is
CC afflicted with breast cancer by examining the correlation between the
CC expression of certain markers and the cancerous state of breast cells.
CC The polynucleotides and encoded polypeptides are potential markers for
CC detecting, diagnosing, monitoring, characterizing treating and
CC potentially preventing breast cancer. The polynucleotides and encoded
CC polypeptides are also useful for isolating compounds with cytostatic
CC activity.
XX SQ Sequence 470 BP; 144 A; 92 C; 116 G; 118 T; 0 other;

Alignment Scores:
Pred. No.: 7,15e-64 Length: 470
Score: 630.00 Matches: 120
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 61.88% Indels: 0
DB: 22 Gaps: 0

US-09-895-298a-83 (1-190) x AAL18591 (1-470)
OY 71 ThrArgProGlyTyrLeuTrpValValTrpIleTyrArgAsnLeuIleGlySerValHis 90
DB 5 ACACGGCCCTGGTACCTGGGTTGTTGGATCTATCGAGACCTCATTTGGAAGTGCAC 64
OY 91 PhePhePheIleLeuThrLeuIleValLeuIleIleThrTyrLeuTyrTrpGlnIleThr 110
DB 65 TTTCTTTTATCTCATCCCTCATTTGCTAATCATCATCTATCTTACGGCAGATCACA 124
OY 111 GluGlyArgLysIleMetIleArgLeuLeuHisGluGlnIleIleAsnGluGlyLysASP 130
DB 125 GAGCGAAGAGAAATTTGATTAAGCTGCTCCATGACCAATCTTAAATAGGCAAGAT 184
OY 131 LysMetPheLeuIleGluLysLeuIleLysLeuGlnAspMetGluLysLysAlaAsnPro 150
DB 185 AAAATGTTCTCTGATAGAAAATGTATGATCAAGCTGCAGATATGAGAAAGCAACCCC 244
OY 151 SerSerLeuValLeuGluArgArgGluValGluGlnGlnGlyPheLeuHisLeuGlyGlu 170
DB 245 ACCTGACTTGTCTTGGAAGAGAGAGGTGGAGCAACAAGGCTTTTGTGATTTGGGGGAA 304
OY 171 HisAspGlySerLeuAspLeuArgSerArgArgSerValGlnGluGlyAsnProArgGala 190
DB 305 CATGATGCGAGTCTTGACTTGGCATCTAAGAAATCAGTTCAAGAAAGATATCCAAAGGCC 364

```

```

RESULT 15
ID AAL09919
AC AAL09919 standard; cDNA; 501 BP.
XX AC AAL09919;
XX DT 07-DEC-2001 (first entry)
XX DE Human breast cancer expressed polynucleotide 2376.
XX DE Human breast cancer; cell marker; cytostatic; ss.
XX OS Homo sapiens.
XX PN WO200151628-A2.
XX PD 19-JUL-2001.
XX PF 10-JAN-2001; 2001WO-US00798.
XX PR 14-JAN-2000; 2000US-0176077.
XX PR 14-MAR-2000; 2000US-0189167.
XX PR 24-MAR-2000; 2000US-0192099.
XX PR 29-MAR-2000; 2000US-0193480.
XX PR 15-MAY-2000; 2000US-0205230.
XX PR 09-JUN-2000; 2000US-0211315.
XX PR 25-JUL-2000; 2000US-0220534.
XX PA (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
XX PI Lillie J, Xu Y, Wang Y, Steinmann K;
XX DR WPI; 2001-451856/48.
XX PT New peptide useful as a marker for the diagnosis of breast cancer -
XX PS Claim 1; Page 455; 3695pp; English.
XX CC The invention relates to human breast cancer expressed polynucleotides
CC (AAU07544-AAU6789) and methods of assessing whether a patient is
CC afflicted with breast cancer by examining the correlation between the
CC expression of certain markers and the cancerous state of breast cells.
CC The polynucleotides and encoded polypeptides are potential markers for
CC detecting, diagnosing, monitoring, characterizing treating and
CC potentially preventing breast cancer. The polynucleotides and encoded
CC polypeptides are also useful for isolating compounds with cytostatic
CC activity.
XX SQ Sequence 501 BP; 147 A; 101 C; 128 G; 122 T; 3 other;

Alignment Scores:
Pred. No.: 4,02e-63 Length: 501
Score: 614.00 Matches: 119
Percent Similarity: 99.17% Conservative: 0
Best Local Similarity: 99.17% Mismatches: 1
Query Match: 61.28% Indels: 0
DB: 22 Gaps: 0

US-09-895-298a-83 (1-190) x AAL09919 (1-501)
OY 71 ThrArgProGlyTyrLeuTrpValValTrpIleTyrArgAsnLeuIleGlySerValHis 90
DB 36 ACACGGCCCTGGTACCTGGGTTGTTGGATCTATCGAGACCTCATTTGGAAGTGCAC 95
OY 91 PhePhePheIleLeuThrLeuIleValLeuIleIleThrTyrLeuTyrTrpGlnIleThr 110
DB 96 TTTCTTTTATCTCATCCCTCATTTGCTAATCATCATCTATCTTACGGCAGATCACA 155
OY 111 GluGlyArgLysIleMetIleArgLeuLeuHisGluGlnIleIleAsnGluGlyLysASP 130
DB 156 GAGCGAAGAGAAATTTGATTAAGCTGCTCCATGACCAATATTTAATAGGCAAGAT 215
OY 131 LysMetPheLeuIleGluLysLeuIleLysLeuGlnAspMetGluLysLysAlaAsnPro 150

```

```

Db 216 AAAATGTTCTGATAGAAAAAATTGATCAAGCTGCAGGATATGGAGAGACAAGCAAAACCCC 275
Qy 151 SerSerLeuValLeuGluArgArgGluValGluGluGluGlyPheLeuHisLeuGlyGlu 170
Db 276 AGCTCACCTTGTTGTAAGAGAGAGAGGCTTGTGCAACAAAGGCTTTTGCATTGGGGGAA 335
Qy 171 HisAspGlySerLeuAspLeuArgSerArgArgSerValGluGlyAsnProArgAla 190
Db 336 CATGATGGCAGCTCTTGACCTTGCATCTAGAAANATCAGTTCAAGAAAGTAATCCAAAGGCC 395

```

Search completed: November 9, 2002, 04:48:43  
 Job time : 303 secs

**THIS PAGE BLANK (USPTO)**